

Carolina Salcedo Roca

PAPERS, ABSTRACTS/COMMUNICATIONS & PATENTS

PAPERS

1. Salcedo C, Fernández AG, Palacios JM. A1 and A2 adenosine receptors mediate opposite effects on NSAID induced gastric ulcers in the rat. *Inflammopharmacol*, 1995, 3: 393-399.
2. Godessart N, Salcedo C, Fernandez AG, Palacios JM. Role of COX-2 inhibition on the formation and healing of gastric ulcers induced by indomethacin in the rat. *Adv Exp Med Biol* 1999, 469:157-63. Doi: 10.1007/978-1-4615-4793-8_24
3. Fernández AG, Salcedo C, Palacios JM. Aspirin, salicylate and gastrointestinal injury. *Nature Med*, 1995, 1: 602. doi: 10.1038/nm0795-602a.
4. Salcedo C. Mecanismos serotoninérgicos implicados en le rascado inducido por 5-MeOT en la rata. *Publicaciones de la Universidad Autónoma de Barcelona*; 1995.
5. C Salcedo, S Davalillo, J Cabellos, C Lagunas, D Balsa, S. Pérez-del-Pulgar, M Ballarín, AG Fernández.. In vivo and in vitro pharmacological characterisation of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. *Br J Pharmacol* 2009 Mar;156(5):807-17. Epub 2009 Feb 16 doi: 10.1111/j.1476-5381.2008.00082.x
6. Peretto I, Forlani R, Fossati C, Giardina GA, Giardini A, Guala M, La Porta E, Petrillo P, Radaelli S, Radice L, Raveglia LF, Santoro E, Scudellaro R, Scarpitta F, Bigogno C, Misiano P, Dondio GM, Rizzi A, Armani E, Amari G, Civelli M, Villetti G, Patacchini R, Bergamaschi M, Delcanale M, Salcedo C, Fernández AG, Imbimbo BP. Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1). *J Med Chem*. 2007 Apr 5;50(7):1571-83. Epub 2007 Mar 13. doi: 10.1021/jm061159a.
7. Salcedo C, Davalillo S, Catena J, Enrich A, Fernández-Serrat A, Miquel I, Sanagustín J, Farrerons C, Lagunas C, Balsa D, Fernández AG Functional characterization of SVT-40776, a novel and potent M3 receptor antagonist, on mice detrusor and atria isolated preparations using in vitro and ex vivo protocols *Br J Pharmacol* 2002, 136 (sup): 45P. doi: 10.1111/j.1476-5381
8. Dolors Balsa, Joan Cabellos, Oscar Rey, Carme Serra, Alicia Enrich, Teresa Pellicer, Sandra de Davalillo, Carme Lagunas, Carolina Salcedo, Andrés G. Fernandez Evaluation of a novel PPAR gamma modulator with in vivo antiadipogenic properties. *Diabetologia* 2006, 49[Suppl1]:132-133
9. C. Salcedo, C. Pontes, and M. Merlos. Is the H4 receptor a new drug target for allergies and asthma?. *Frontiers in bioscience (Elite edition)* 5 (2012): 178-187. doi: 10.2741/e606
10. Joubert P, Ketteler M, Salcedo C, Perello J. Hypothesis: Phytate is an important unrecognised nutrient and potential intravenous drug for preventing vascular calcification. *Med Hypotheses*. 2016 Sep;94:89-92. doi: 10.1016/j.mehy.2016.07.005.
11. Ferrer MD, Pérez MM, Cànaves MM, Buades JM, Salcedo C, Perelló J. A novel pharmacodynamic assay to evaluate the effects of crystallization inhibitors on calcium phosphate crystallization in human plasma. *Sci Rep*. 2017 Jul 31;7(1):6858. doi: 10.1038/s41598-017-07203-x.
12. Perelló J, Gómez M, Ferrer MD, Rodríguez NY, Salcedo C, Buades JM, Pérez MM, Torregrosa JV, Martín E, Maduell F. SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels. *J Nephrol*. 2018 Apr;31(2):287-296. doi:10.1007/s40620-018-0471-9.
13. Ferrer MD, Ketteler M, Tur F, Tur E, Isern B, Salcedo C, Joubert PH, Behets GJ, Neven E, D'Haese PC, Perelló J. Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification. *PLoS One*. 2018 May 9;13(5):e0197061. doi:10.1371/journal.pone.0197061.
14. Perelló J, Joubert PH, Ferrer MD, Canals AZ, Sinha S, Salcedo C. First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification. *Br J Clin Pharmacol*. 2018 Dec;84(12):2867-2876. doi: 10.1111/bcp.13752.

15. Salcedo C, Joubert PH, Ferrer MD, Canals AZ, Maduell F, Torregrosa V, Campistol JM, Ojeda R, Perelló J. A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients. *Br J Clin Pharmacol*. 2019 Apr;85(4):796-806. doi: 10.1111/bcp.13863.
16. Brandenburg VM, Sinha S, Torregrosa JV, Garg R, Miller S, Canals AZ, Bahr D, Joubert PH, Salcedo C, Carroll KJ, Gold A, Perelló J. Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis. *J Nephrol*. 2019 Oct;32(5):811-821. PubMed PMID: 31401795. doi: 10.1007/s40620-019-00631-0.
17. Zbirnyk A, Ferrer MD, Bogdanova M, Pérez MM, Salcedo C, Kaljusto ML, Kvitting JE, Stensløykken KO, Perelló J, Vaage J. SNF472, a novel anti-crystallization agent, inhibits induced calcification in an in vitro model of human aortic valve calcification. *Vascul Pharmacol*. 2019 Nov - Dec;122-123:106583.. PubMed PMID: 31437530. doi: 10.1016/j.vph.2019.106583
18. Bellasi A, Raggi P, Bover J, Bushinsky DA, Chertow GM, Ketteler M, Rofriguez M, Sinha S, Salcedo C, Garg R, Gold A, Perelló J. Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification. *Clin Kidney J*. 2019. sfz144, doi: 10.1093/ckj/sfz144.
19. Raggi P, Bellasi A, Bushinsky D, Bover J, Rodriguez M, Ketteler M, Sinha S, Salcedo C, Gillotti K, Padgett C, Garg R, Gold A, Perelló J, Chertow GM. Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study. *Circulation*. 2020 Mar 3;141(9):728-739.. Epub 2019 Nov 11. PMID: 31707860. doi: 10.1161/CIRCULATIONAHA.119.044195
20. Perelló J, Ferrer MD, Del Mar Pérez M, Kaesler N, Brandenburg VM, Behets GJ, D'Haese PC, Garg R, Isern B, Gold A, Wolf M, Salcedo C. Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis. *Br J Pharmacol*. 2020 Jun 18;177(19):4400–15.. Epub ahead of print. PMID: 32557649; PMCID: PMC7484563. doi: 10.1111/bph.15163
21. Perez MM, Ferrer MD, Lazo-Rodriguez M, Canals AZ, Banon-Maneus E, Campistol JM, Miller S, Garg R, Gold A, Salcedo C, Perelló J. A novel assay to measure calcification propensity: from laboratory to humans. *Sci Rep*. 2020 Oct 16;10(1):17578.. PMID: 33067536; PMCID: PMC7568551. doi: 10.1038/s41598-020-74592-x
22. Zbirnyk A, Perez MDM, Blasco M, Stensløykken KO, Ferrer MD, Salcedo C, Vaage J. A Novel Ex Vivo Model of Aortic Valve Calcification. A Preliminary Report. *Front Pharmacol*. 2020 Dec 17;11:568764.. PMID: 33390945; PMCID: PMC7773652. doi: 10.3389/fphar.2020.568764
23. Perelló J, Alberti J, Torres JV, Ferrer MD, Perez MM, Bassissi F, Gold A, Raggi P, Chertow GM, Salcedo C. Hexasodium fytate exposure-response correlations in a randomized, placebo-controlled study of patients on dialysis with cardiovascular calcification. *Front Pharmacol*. 2024 Feb 7;15:1325186.. eCollection 2024. doi: 10.3389/fphar.2024.1325186

ABSTRACTS/COMMUNICATIONS

1. Salcedo C, Puig J, Palacios JM, Fernández AG. "Phosphodiesterase 4 inhibition, a new mechanism to maintain and promote gastric and intestinal mucosal integrity against NSAID-induced injury in the rat". *Gastroenterology*, 1998, 114, P. G1126-G1126. New Orleans (USA)
2. Crespo MI, Gràcia J, Vega A, Salcedo C, Fernández AG, Domènech T, Beleta J, Segarra V, Ryder H, Palacios JM. "2,5 Dihydropyrazolo [4,3-c] Quinolin-3-ones, a new class of PDE4 inhibitors with antiulcer activity". XVth EFMC International Symposium on Medicinal Chemistry, 1998, P153. Edinburgh (Scotland)
3. Salcedo C, Puig J, Fernández AG, Palacios JM. "*In vivo* modulation of gastric acid secretion by phosphodiesterase 4 inhibitors in the rat". *Meth Find Exp Clin Pharmacol*, 1997, 19 (suppl. A), 169.
4. Godessart N, Salcedo C, Fernández AG, Palacios JM. "Role of COX-2 inhibition on the formation and healing of gastric ulcers induced by indomethacin in the rat". 5th International Conference on Eicosanoids & other Bioactive Lipids in Cancer, Inflammation and Related Diseases, 1997, Abstract book, p. 143. La Jolla (USA).
5. Bou J, Lluprà J, Cardelús I, Puig J, Salcedo C, Gras J, Beleta J, Fernández AG, Llenas J, Berga P, Gristwood RW, Palacios JM. "LAS 31025, a new antiasthmatic compound combining airway antiallergic and bronchodilatory properties". 3rd International Conference on Cyclic Phosphodiesterases: From Genes to Therapies, 1996, Glasgow (Scotland).

6. Bou J, Beleta J, Cardelús I, Miralpeix M, Puig J, Doménech T, Salcedo C, Gras J, Fernández AG, Llenas J, Berga P, Gristwood RW, Palacios JM. "Characterization of LAS 31025: a new selective PDE IV inhibitor for bronchial asthma". 3rd International Conference on Cyclic Phosphodiesterases: From Genes to Therapies, 1996, Glasgow (Scotland).
7. Godessart N, Salcedo C, Fernández AG, Palacios JM. "Antiinflammatory and gastrointestinal lesive effects of novel and classical NSAIDs in rats after acute and subacute treatments". Prostaglandins, Leukotrienes and Essential Fatty Acids, 1996, 55 (suppl. 1), 93.
8. Salcedo C, Puig J, Fernández AG, Palacios JM. "Peripheral 5-HT_{1A} and 5-HT_{1D} receptors are involved in serotonergic induced hindlimb scratching". Meth Find Exp Clin Pharmacol, 1995, 17 (suppl. A), 128.
9. Mengod G, Cortes R, Salcedo C, Palacios JM. 5-Hidroxitryptamnine-4 receptors (5-HT_{4R}) in the guinea pig basal ganglia: presynaptic localization in the striatonigral pathway and codistributed with 5-HT_{1D} receptors. American Society for Neuroscience. Annual Meeting 1995; San Diego (USA) . Society for Neurosceince Abstracts, 1995, 21 (3): Abstract 728.4, 1856.
10. Salcedo C, Kelly ME, Fernández AG, Beleta J, Puig J, Berga P, Gristwood RW, Costall B, Palacios JM. Importancia de la estereoselectividad en los efectos centrales y periféricos de los antagonistas 5-HT₃: el ejemplo de pancoprida. XVII Reunión Nacional de la Sociedad Española de Farmacología. Valladolid (Spain). Rev Farmacol Clin Exp (Núm. Especial), 1993, p. 197.
11. Beleta J, Salcedo C, Doménech T, O'Neill MF, Fernández AG. Efectos centrales de los antihistamínicos ebastina, loratadina y cetirizina en modelos experimentales. XVIII Congreso Nacional de la Sociedad Española de Alergia e Inmunología Clínica; 1992, Sevilla (Spain).
12. Fernández AG, Beleta J, Kelly ME, Salcedo C, Puig J, Domeney AM, Berga P, Gristwood RW, Costall B. Pancopride, a new 5-HT₃ antagonist with potent anxiolytic properties in rodents and primates. Behav Pharmacol, 1992, 3, suppl. 1, 43.
13. Palacios JM, Salcedo C, Puig J, Gristwood RW, Fernández AG. Hindlimb scratching in rats discriminates amongst sumatryptan and other 5-HT_{1D} agonists. Society for Neuroscience Abstracts, 1992, 18, 1380 (Abstract 579.7).
14. De Davalillo S, Pellicer T, Lagunas C, Marchan S, Catena J, Balsa D, Salcedo C, Perez-del-Pulgar S, Fernandez AG. "Pharmacological profile of SVT004703, a new oral proapoptotic compound for the treatment of cancer". 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2006. EJC supplements. Volume 4 (12), P642.
15. Balsa D, Cabellos J, Rey O, Serra C, Enrich A, Pellicer T, de Davalillo S, Lagunas C, Salcedo C, Fernández AG. "Evaluation of a novel PPAR γ modulator with *in vivo* antiadipogenic properties". Diabetologia (2006) 49:[Suppl1] 132-133. Comunicación oral.
16. Rey O, Balsa D, Cabellos J, Serra C, Enrich A, Pellicer T, De Davalillo S, Lagunas C, Salcedo C, Fernández AG. "PPAR γ modulators: An Induced Fit study". Meeting Europeo de usuarios de Schrödinger, Barcelona. Comunicación oral.
17. Lagunas C, Sanagustín J, Toribio F, Balsa D, Salcedo C, Fernández AG. "Tissue distribution selectivity and poor brain penetration of [¹⁴C]-SVT-40776, a new agent to treat overactive bladder". Methods and Findings in Experimental and Clinical Pharmacology, 2005; 27 (suppl.2): P-133, 181.
18. Salcedo C, Cabellos J, Balsa D, Davalillo S, Lagunas C, Fernández AG. "Adipose tissue remodeling induced by thizolidinediones in obese mice". Methods and Findings in Experimental and Clinical Pharmacology, 2005; 27 (suppl.2): P-111, 168.
19. Balsa D, Enrich A, Pellicer T, Salcedo C, Lagunas C, Fernández AG. "Functional tissue selectivity of SVT-40776: Inhibition of muscarinic M3-mediated phosphoinosite response in urinary bladder and salivary glands". Methods and Findings in Experimental and Clinical Pharmacology, 2005; 27 (suppl.2): P-108, 165.
20. Balsa D, Salcedo C, Enrich A, Davalillo S, Cabellos J, Fernández AG. "Functional bladder selectivity of SVT-40776: A comparative study". ICS / IUGA Annual Meeting, 2005, P 284.

21. Fernández AG, Viayna C, Salcedo C, Davalillo S, Sanagustín J, Lagunas C, Rigau D, López R. "Bladder selectivity of SVT-40776: A pharmacokinetic / pharmacodynamic (PK/D) analysis based on preclinical and clinical studies". ICS / IUGA Annual Meeting, 2005, P 298.
22. Cabellos J, Balsa D, Salcedo C, Enrich A, Davalillo S, Pellicer T, Lagunas C, Serra C, Fernández AG. "Comparative effects of rosiglitazone and balaglitazone on adipose tissue remodeling in diet-induced obese mice". 3rd International Symposium on PPARs Efficacy and Safety, 2005.
23. Balsa D, Salcedo C, Enrich A, Davalillo S, Cabellos J, Pellicer T, Lagunas C, Catena J, Fernández AG. "SVT-40776: a selective, competitive and reversible antagonist of the human recombinant muscarinic M3 receptor". ICS / IUGA Annual Meeting, 2004, P 260.
24. Salcedo C, Balsa D, Davalillo S, Enrich A, Pellicer T, Lagunas C, Catena J, Fernández-Serrat A, Farrerons C, Fernández AG. "SVT-40776, a new selective M3 muscarinic antagonist: human receptor binding profile and bladder effects in the guinea pig". *Neurology Urodynamics*, 2003; 22 (5): 382-38.
25. Salcedo C, Davalillo S, Catena J, Enrich A, Fernández-Serrat A, Miquel I, Sanagustín J, Farrerons C, Lagunas C, Balsa D, Fernández AG. "Functional characterization of SVT-40776, a novel and potent M3 receptor antagonist, on mice detrusor and atria isolated preparations using *in vitro* and *ex vivo* protocols". *Br J. Pharmacol* 2002; 136(suppl) 45P.
26. Davalillo S, Catena J, Lagunas C, Balsa D, Fernández AG, Salcedo C. "*In vitro* and *ex vivo* bladder vs. atria functional selectivity of a range of muscarinic receptor antagonists in mice". *Meth Find Exp Clin Pharmacol*; 2002, 24 (suppl. A), 158.
27. Farrerons C, Catena J, Fernández-Serrat A, Miquel I, Llorens O, Lagunas C, Balsa D, Salcedo C, Pérez JJ, Fernández AG. "Diarylimidazo [1,2-a]pyridine derivatives as a new class of selective COX-2 inhibitors". 11th RSC-SCI Medicinal Chemistry, P2, 2001, P2.
28. Miquel I, Catena J, Farrerons C, Fernández-Serrat A, Balsa D, Lagunas C, Salcedo C, Pérez JJ, Fernández AG. "Diaryl [1,2-a]triazine derivatives as a new class of selective COX-2 inhibitors". Hungarian-German-Italian-Polish Joint Meeting on Medicinal Chemistry. Budapest (Hungary), 2001.
29. Catena J, Farrerons C, Fernández-Serrat A, Miquel I Llorens O, Lagunas C, Balsa D, Salcedo C, Pérez JJ, Fernández AG, "Diaryl [1,2- α]pyrimidine derivatives as a new class of selective COX-2 inhibitors". Trends in drug research- 13th Noordwijkerhout- Camerino Symposium. 2001.
30. Salcedo C, Lagunas C, Balsa D, Davalillo S, Enrich A, Farrerons C, Fernández-Serrat A, Miquel I, Catena J, Fernández AG. "Pharmacological profile of SVT-2016, a new highly selective COX-2 inhibitor". EPHAR. Lyon (Francia) 2001.
31. Farrerons C, Llorens O, Fernández-Serrat A, Miquel I, Lagunas C, Fernández AG, Pérez J.J. "Synthesis and biological evaluation of 1,3,4-triaryl lactams as a new class of selective cyclooxygenase-2-inhibitors". 20th Congreso de la Real Sociedad Española de Química Farmacéutica. Valencia (Spain), 1999.
32. J.M. Buades, I. Fernández, D. Gómez, M.D. Ferrer, B. Isern, C. Salcedo, J. Perelló. Medición de las concentraciones en plasma del inhibidor de la cristalización de sales cálcicas SNF472 durante su infusión pre- y post-filtro en un circuito de hemodiálisis *in vitro*. SENEPRO 2013 (XLIII CONGRESS de la Sociedad Española de Nefrología). Bilbao (Spain), 2013
33. M. Ketteler, M.D. Ferrer, F. Tur, B. Isern, C. Salcedo, P.H. Joubert, J. Perelló. SNF472 inhibits vitamin D induced cardiovascular calcification in rats. *Kidney Week 2013*(World Nephrology Congress, American Society of Nephrology). *J Am Soc Nephrol* (2013) 24 (Abstract Supplement): 561A. Atlanta (USA) 2013
34. J. Perelló, C. Salcedo, M. Ketteler, F. Tur, E. Tur, B. Isern, P.H. Joubert, M.D. Ferrer. Intravenous SNF472 inhibits vitamin D induced cardiovascular calcification in rats. *Kidney Week 2014*(World Nephrology Congress, American Society of Nephrology). REFERENCE:*J Am Soc Nephrol* (2014) 25 (Abstract Supplement): 233A. Philadelphia (USA), 2014
35. J. Perelló, C. Salcedo, P.H. Joubert, A.Z. Canals, M.D. Ferrer. First-time-in-human phase 1 clinical trial in healthy volunteers with SNF472, a novel inhibitor of vascular calcification . 52nd Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) REFERENCE: *Nephrol Dial Transplant* (2015) 30 (suppl 3): iii592 / F1000Research 2015, 4:895 (poster) (doi: 10.7490/f1000research.1110643.1) London (UK), 2015

36. J. Perelló, C. Salcedo, M. Ketteler, F. Tur, B. Isern, P.H. Joubert, M.D. Ferrer. Subcutaneous SNF472 inhibits the progression of Vitamin D induced cardiovascular calcification in rats. 52nd Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) REFERENCE: Nephrol Dial Transplant (2015) 30 (suppl 3): iii588 / F1000Research 2015, 4:896 (poster) (doi: 10.7490/f1000research.1110644.1) London (UK), 2015
37. J. Perelló, C. Salcedo, E. Neven, G.J. Behets, P.H. Joubert, P.C. D'Haese, M.D. Ferrer. SNF472 inhibits cardiovascular calcification in uremic rats. Kidney Week 2015 (World Nephrology Congress, American Society of Nephrology). REFERENCE: J Am Soc Nephrol (2015) 26 (Abstract Supplement): 761A. San Diego (USA), 2015
38. Perelló J, Salcedo C, Joubert PH, Canals AZ, Ferrer MD. First Experience with a Novel Inhibitor of Vascular Calcification (SNF472) in Healthy Volunteers and ESRD Patients on Hemodialysis. Kidney Week 2015 (World Nephrology Congress, American Society of Nephrology). REFERENCE: J Am Soc Nephrol (2015) 26 (Abstract Supplement): 38A. San Diego (USA), 2015
39. Perelló J, Gomez M, Rodríguez NY, Salcedo C, Ferrer MD, Buades JM, Pérez MM, Martín E, Maduell F. In Vitro Dialysability of SNF472, a Novel Inhibitor of Vascular Calcification, Using Conventional Hemodialysis and Hemodiafiltration. Kidney Week 2015 (World Nephrology Congress, American Society of Nephrology). REFERENCE: J Am Soc Nephrol (2015) 26 (Abstract Supplement): 1034A. San Diego (USA), 2015
40. M.M. Pérez, M.D. Ferrer, C. Salcedo, M. Martorell, J. Perelló. SNF472 inhibe la calcificación cardiovascular en ratas inducida por vitamina D. XII Simposio de Investigadores Jóvenes Químicos RSEQ-Sigma Aldrich REFERENCE: Scientific Program: 169. Barcelona (Spain), 2015
41. J. Perelló, C. Salcedo, P.H. Joubert, A.Z. Canals, M.D. Ferrer. A Phase 1 clinical trial in healthy volunteers and hemodialysis patients with SNF472, a novel inhibitor of vascular calcification. CKD-MBD WG ERA-EDTA Meeting 2015. Milán (Italia), 2015
42. C. Salcedo, M.D. Ferrer, A.Z. Canals, M.M Pérez, P.H. Joubert, J. Perelló. SNF472 is a molecule with the potential to inhibit cardiovascular calcification in end-stage renal disease patients on hemodialysis. National Kidney Foundation Spring Clinical Meeting Meeting Boston (USA), 2016
43. J. Perelló, M.M. Pérez, M. Lazo, E. Bañón, J.M. Campistol, C. Salcedo, M.D. Ferrer. SNF472 pharmacokinetics-pharmacodynamics in a vitamin d-induced calcification rat model. 53rd Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA 2016) Viena (Austria), 2016
44. C. Salcedo, J. Perelló, R. Ojeda, P.H. Joubert, M. Arias, AZ. Canals, M.D. Ferrer, V. Torregrosa, JM Campistol, F.Maduell A phase 1b/2a randomised, placebo-controlled clinical trial with snf472 in haemodialysis patients. 53rd Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA 2016) Viena (Austria), 2016
45. Hyusein, V. Brandenburg, M.D. Ferrer, A.Z. Canals, C. Salcedo, J. Perelló, J. Floege, N. Kaesler. SNF472 - a potential novel calcification inhibitor in CKD-MBD: 53rd Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA 2016) Viena (Austria) , 2016
46. M.D. Ferrer, C. Salcedo, A.Z. Canals, M. Lazo, J.M. Campistol, J. Perelló. Intravenous SNF472 (a novel inhibitor of vascular calcification) does not affect bone histology and histomorphometry in healthy and uremic animal models CKD-MBD WG ERA-EDTA "The Bone in Chronic Kidney Disease" Meeting 2016. Amsterdam (Holanda), 2016
47. N. Kaesler, A. Hyusein, M.D. Ferrer, A.Z. Canals, C. Salcedo, J. Perelló, J. Floege, V. Brandenburg. SNF472 - a potential novel calcification inhibitor in CKD-MBD Kidney Week 2016 (World Nephrology Congress, American Society of Nephrology). Chicago (Estats Units), 2016
48. C. Salcedo, J. Perelló, R. Ojeda, P.H. Joubert, M. Arias, A.Z. Canals, M.D. Ferrer, M.M. Pérez, V. Torregrosa, F. Maduell. Safety, pharmacokinetics and pharmacodynamics of snf472 in hemodialysis patients: new data from a phase 1b/2a randomised placebo-controlled clinical trial Kidney Week 2016 (World Nephrology Congress, American Society of Nephrology). Chicago (USA), 2016

49. J. Perelló, M. Gómez, M.D. Ferrer, N.Y. Rodríguez, C. Salcedo, J.M. Buades, M.M. Pérez, E. Martín, F. Maduell SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels. 54th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA 2017). Madrid (Spain), 2017
50. M.D. Ferrer, M.M. Pérez, M. Lazo, E. Bañón, J.M. Campistol, R. Ojeda, P.H. Joubert, M. Arias, A.Z. Canals, J.V. Torregrosa, F. Maduell, C. Salcedo, J. Perelló. Preclinical and clinical validation of a novel pharmacodynamic assay to evaluate the effect of calcification inhibitors on calcium phosphate crystallization in plasma. 54th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA 2017). Madrid (Spain), 2017
51. V. Brandenburg, S. Sinha, V. Torregrosa, C. Salcedo, P. Klassen, R. Garg, P.H. Joubert, J. Perelló. Phase 2 Open Label Single Arm Repeat Dose Study to Assess the Effect of SNF472 on Wound Healing in Uraemic Calciphylaxis Patients. Kidney Week 2017 (World Nephrology Congress, American Society of Nephrology). New Orleans (USA), 2017
52. Zabinnyk, M. Bogdanova, M.D. Ferrer, M.M. Perez, M.L. Kaljusto, K-O Stensløkken, J. Perelló, C. Salcedo, J. Vaage. SNF472 inhibits human aortic valve calcification in vitro. 55th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA 2018) Copenhagen (Denmark), 2018
53. V. Brandenburg, S. Sinha, J.V. Torregrosa, L. Berman, S. Miller, A.Z. Canals, D. Bahr, P. Klassen, P.H. Joubert, C. Salcedo, R. Garg, J. Perelló. A Phase 2 Open-Label Single-Arm Study to Assess the Effect of SNF472 on Wound Healing in Calciphylaxis (Calcific Uremic Arteriopathy) Patients. 55th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA 2018) Copenhagen (Denmark), 2018
54. M.D. Ferrer, M.M. Pérez, A.Z. Canals, C. Salcedo, J. Perelló. Pharmacokinetics and pharmacodynamics of SNF472 in calciphylaxis patients – Results from a phase 2 clinical trial (SNFCT2015_04). Kidney Week 2018 (World Nephrology Congress, American Society of Nephrology). San Diego (USA), 2018
55. L. Gould, S. Sinha, V. Brandenburg, G.M. Chertow, S. Miller, A.Z. Canals, D. Bahr, C. Salcedo, R. Garg, A. Gold, J. Perelló. Improvements in Calcific Uremic Arteriopathy Wound Healing During SNF472 Treatment, Results of A Phase 2 Trial. 5th Annual IWH (Innovations in Wound Healing) Conference. Florida (USA), 2018
56. L. Gould, S. Sinha, V. Brandenburg, G.M. Chertow, S. Miller, A.Z. Canals, C. Salcedo, R. Garg, A. Gold, J. Perelló.
57. Improvements in Calcific Uremic Arteriopathy Wound Healing During SNF472 Treatment, Results of A Phase 2 Trial. Symposium on Advanced Wound Care Spring/WHS Annual Meeting (SAWC Spring/WHS). Texas (USA), 2019
58. P. Raggi, A. Bellasi, J. Bover, J.M. Rodríguez, M. Ketteler, S. Sinha, G.M. Chertow, D. Businsky, C. Salcedo, R. Garg, A. Gold, J. Perelló. A double-blind, randomised, placebo-controlled phase 2b study to assess the effect of SNF472 added to standard of care on progression of cardiovascular calcification in patients with end-stage renal disease on maintenance haemodialysis (CaLIPSO study). 56th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA 2019). Budapest (Hungary), 2019
59. S. Sinha, G.M. Chertow, V. Brandenburg, L. Gould, S. Miller, C. Salcedo, R. Garg, A. Gold, J. Perelló. Design of a phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of SNF472 for the treatment of calcific uremic arteriopathy (calciphylaxis). 56th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA 2019). Budapest (Hungary) , 2019
60. G.J. Behets, M.D. Ferrer, M.M. Pérez, C. Salcedo, J. Perelló, C. Salcedo. In vitro effects of SNF472 on osteoblast cell culture. 56th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA 2019) Budapest (Hungary), 2019
61. S. Sinha, G.M. Chertow, V. Brandenburg, L. Gould, S. Miller, C. Salcedo, K.J. Carroll, R. Garg, A. Gold, J. Perelló.
62. Design of a randomized, double-blind, placebo-controlled phase 3 trial to examine the efficacy and safety of SNF472 for treating calcific uremic arteriopathy (calciphylaxis). UK Kidney Week 2019. Brighton (UK), 2019
63. E. McMullen, S. Sinha, L. Gould, V. Brandenburg, G.M. Chertow, S. Miller, A.Z. Canals, C. Salcedo, R. Garg, A. Gold, J. Perelló. TÍTULO: A Phase 2 trial showing improvements in calcific uremic arteriopathy (calciphylaxis) wound healing,

pain, and quality of life during SNF472 Treatment. Conference of the British Association of Dermatologists. Liverpool (UK), 2019

64. M.M Pérez, M.D. Ferrer, J. Ortega-Castro, F. Bassissi, J. Perelló, C. Salcedo. PEGylation of inositol hexaphosphate (InsP6) decreases its binding affinity for hydroxyapatite and its capacity to inhibit plasma calcification in vitro. *Kidney Week 2019 (World Nephrology Congress, American Society of Nephrology)* Washington D.C. (USA) DATE: 2019
65. M.D. Ferrer, M.M Pérez, F. Bassissi, J. Perelló, C. Salcedo. SNF472 is more efficacious in vivo than its 4,6-bisPEGylated derivative in inhibiting vascular calcification in rats *Kidney Week 2019 (World Nephrology Congress, American Society of Nephrology)*. Washington D.C. (USA), 2019
66. F. Bassissi, M.D. Ferrer, M.M. Pérez, J. Perelló, C. Salcedo. SNF472, A New Therapeutic Approach to Improve Outcomes in CKD Patients with PAD. *Poster, Kidney Week 2019 (World Nephrology Congress, American Society of Nephrology)*. Washington D.C. (USA), 2019.
67. S. Sinha, G.M. Chertow, V. Brandenburg, L. Gould, S. Miller, C. Salcedo, K.J. Carroll, C. Padgett, R. Garg, A. Gold, J. Perelló. Outcomes Assessment in a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of SNF472 for Treating Calciphylaxis. *Poster, Kidney Week 2019 (World Nephrology Congress, American Society of Nephrology)*. Washington D.C. (USA), 2019.
68. P. Raggi, A. Bellasi, J. Bover, J.M. Rodriguez, M. Ketteler, S. Sinha, G.M. Chertow, D. Bushinsky, K. Gillotti, K.J. Carroll, C. Salcedo, R. Garg, A. Gold, J. Perelló. Effect of SNF472 on Progression of Cardiovascular Calcification in Patients on Hemodialysis (Results of a Phase 2b Randomized Controlled Study: CaLIPSO). *Oral Presentation, Kidney Week 2019 (World Nephrology Congress, American Society of Nephrology)*. Washington D.C. (USA), 2019.
69. F. Bassissi, M.D. Ferrer, M.M. Pérez, J. Perelló, C. Salcedo. SNF472 Improves Limb Blood Perfusion and Walking Ability in a Peripheral Artery Disease Vascular Calcification Rat Model. *Poster, 57th Congress of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA 2020)*. Fully Virtual, 2020.
70. M.M. Pérez, M.D. Ferrer, J. Ortega-Castro, F. Bassissi, J. Perelló, C. Salcedo. Myo-inositol Hexaphosphate PEGylation Improves Bioavailability but Reduces Its Anti-Vascular Calcification Effect in Rats. *Poster, 57th Congress of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA 2020)*. Fully Virtual, 2020.
71. F. Bassissi, M.D. Ferrer, M.M. Pérez, J. Perelló, C. Salcedo. SNF472 Improves Limb Blood Perfusion and Walking Ability in a Peripheral Artery Disease Vascular Calcification Rat Model. *Oral, Nephrology Dialysis Transplantation, Volume 35, Issue Supplement_3, June 2020, gfaa144.P1234; 57th ERA-EDTA Congress 2020*. Fully Virtual, 2020.
72. C. Salcedo, A. Zabornyk, M.M. Pérez, M. Blasco, K-O. Stensløkken, M.D. Ferrer, I.J. Vaage. SNF472 Inhibits Heart Valve Calcification in a Novel In Vitro Method Using Porcine Whole Leaflets. *Poster, American Society of Nephrology – Kidney Week 2020*. Fully Virtual, 2020.
73. J. Perelló, J.J. Alberti, J.V. Torres, M.M. Pérez, M.D. Ferrer, F. Bassissi, C. Salcedo. Pharmacokinetics, Pharmacodynamics (PK-PD), and Exposure-Efficacy Evaluation from CaLIPSO, a Phase 2B Study to Assess the Effect of SNF472 on Progression of Cardiovascular Calcification in Patients on Hemodialysis. *Poster, American Society of Nephrology – Kidney Week 2020*. Fully Virtual, 2020.
74. F. Bassissi, M.D. Ferrer, M.M. Pérez, M. Blasco, J. Perelló, C. Salcedo. SNF472 Attenuates the Progression of Femoral Artery Calcification and Recovers Limb Blood Perfusion and Walking Ability in a Rat Model of Peripheral Artery Disease. *Poster, Nephrology Dialysis Transplantation, Volume 36, Issue Supplement_1, May 2021, gfab126.002; 58th ERA-EDTA Congress 2021*. Fully Virtual, 2021.
75. F. Bassissi, M.D. Ferrer, M.M. Pérez, M. Blasco, J. Perelló, C. Salcedo. SNF472 Improves Limb Blood Perfusion and Walking Ability and Inhibits Progression of Calcification in Femoral Arteries in a Rat Model of Peripheral Artery Disease. *Poster, Vascular Annual Meeting (VAM)*. San Diego (USA), 2021.
76. F. Bassissi, D. Saborido, M. Blasco, G. Garaulet, M.M. Pérez, M.D. Ferrer, F. Mulero, C. Salcedo. Assessment of Vascular Calcification Using Micro-CT Quantification in a Vitamin D Rat Model. *Poster, American Society of Nephrology – Kidney Week 2021*. San Diego (USA), 2021.

77. M.M. Pérez, M.D. Ferrer, F. Bassissi, I.J. Jacobs, Q. Li, O.M. Vanakker, L. Dangreau, J. Perelló, C. Salcedo. Hexasodium Fytate (SNF472) Inhibits Ectopic Calcification in Pseudoxanthoma Elasticum Animal Models. *Poster, European Calcified Tissue Society (ECTS) Congress*. Marseille (France), 2024.
78. M.D. Ferrer, M.M. Pérez, M. Blasco, A. López, G. Malagraba, F. Bassissi, J. Perelló, C. Salcedo. Model Severity-Dependent Inhibition of Ectopic Calcification by Hexasodium Fytate (SNF472): Insights from In Vitro and In Vivo Investigations. *Poster, European Calcified Tissue Society (ECTS) Congress*. Marseille (France), 2024.

PATENTS

1. **Carbamates derived from arylalkylamines.** Farrerons, C. Catena, J. Fernández, A. Balsa, D. Bonilla, J. Salcedo, C. Lagunas C. Fernández, A. WO02/00652; 2001-01-03
2. **Substituted isoxazoles and the use thereof as antibiotics.** Farrerons, C. Lagunas, C. Fernández, A. Catena, J. Miquel, I. Balsa, D. Salcedo, C. Toledo, N. Fernández, A; WO03/008395; 2001-07-20.
3. **1-Alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives.** Farrerons, C. Catena, J. Fernández, A. Balsa, D. Toledo, N. Salcedo, C. Lagunas C. Fernández, A. Miquel I. ; WO03043966: 2001-12-20.
4. **New benzamides as PPAR γ modulators.** Fernandez Serrat, A. Serra Comas, C. Balsa Lopez, D. Llebaria Soldevilla, A.Farrerons Gallemi, C. Miquel Bono, I.J.Catena Ruiz, J.L.Lagunas Arnal, C.Cordomi Montoya, A.Salcedo Roca, C.Toledo Mesa, N.Marrero Gonzalez, P.Haro Bautista, D.Fernandez Garcia, A. WO04110983, 2003-06-13.
5. **Substituted imidazopyrimidines for the prevention and treatment of cancer,** Catena Ruiz, J.L. Farrerons Gallemi, C. Fernandez Serrat, A. Serra Comas, C. Balsa Lopez, D. Lagunas Arnal, C. Salcedo Roca, C. Fernandez Garcia, A. WO05014598, 2003-07-30.
6. **Tyrosine derivatives as PPAR- γ -modulators.** Serra Comas, C. Fernandez Serrat, A. Balsa Lopez, D. Masip Masip, I. Catena Ruiz, J.L. Hidalgo Rodriguez, J. Lagunas Arnal, C. Salcedo Roca, C. Fernandez Garcia, A. WO06010775: 2004-07-30.
7. **Dicarbonylic compounds with antibacterial activity.** Hidalgo Rodriguez, J. Serra Comas, C. Rey Puiggròs, O. Balsa Lopez, D. Masip Masip, I. Catena Ruiz, J.L. Lagunas Arnal, C. Salcedo Roca, C. WO06010775; 2007-01-18.
8. **Uso de derivados con enlaces C-O-P en pacientes con fallo renal.** Perelló J, Salcedo C, Ferrer M.D, Isern B, Joubert P.H. P201330383 Priority Country: Spain Priority Date: 15-03-2013 Extended to Countries / status: Spain (granted), EEUU (granted)
9. **Uso de derivados con enlaces C-O-P en pacientes con fallo renal.** Perelló J, Salcedo C, Ferrer M.D, Isern B, Joubert P.H. WO2014140402 Priority Country: Spain Priority Date: 15-03-2013 Extended to Countries / status: EEUU (granted), Canadá (fase nacional), Mexico (national phase), Brasil (national phase), Japan (national phase), China (national phase), Australia (national phase), Russia (national phase), Hong Kong (national phase).
10. **Pautas posológicas de IP y análogos de IP para el tratamiento de calcificaciones ectópicas.** Perelló J, Salcedo C, Canals A.Z. P201830988 Priority Country: Spain Priority Date: 11-10-2018 Extended to Countries / status PCT Phase.
11. **IP and IP analogs dosage regimens for the treatment of ectopic calcifications.** Perelló J, Salcedo C, Canals A.Z. PCT/IB2018/057904 Priority Country: Spain Priority Date: 11-10-2018 Extended to Countries / status: PCT Phase
12. **Inositol phosphate compounds for use in increasing tissular perfusion.** Bassissi F, Salcedo C, Perelló J. EP19382061.0 Priority Country: Spain Priority Date: 30-01-2019 Extended to Countries / status: European Phase
13. **Inositol phosphate compounds for use in increasing tissular perfusion.** Bassissi F, Salcedo C, Perelló J. Ferrer M.D., Pérez M.M. 62913259 Priority Country: USA Priority Date: 10-10-2019 Extended to Countries / status: USA

14. **Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification.** Perelló J, Salcedo C, Ferrer M.D. EP19382990.0 Priority Country: Spain Priority Date: 11-11-2019 Extended to Countries / status: Europe
15. **Compuestos derivados de IP4-4,6 sustituidos.** Pérez M, Ferrer M, Bassissi F, Salcedo C, Serra C, Catena J, Llebaria A, Ortega J, Perelló Nº de solicitud: EP21382075 ("EP'075") Priority Country: Spain Priority Date: 29-11- 2021 Extended to Countries / status: Europe

RESEARCH SUPPORT / PROJECT LEAD

Project Title: **Innocash - New Therapy for the Treatment of Vascular Calcification in Dialysis Patients.**

Funded By: Genome Spain Foundation

Duration: 12/05/2011 31/12/2014

PI: Joan Perello Role: co-Investigator

Project Title: **Request Shareholder Loan To The National Company of Innovation (ENISA)**

Funding: National Innovation Company (ENISA)

Duration: 01/06/2010 - 31/05/2013

PI: Bernat Isern Amengua Role: co-Investigator

Project Title: **Technical Feasibility of a Drug for Heart Disease, Pre-Clinical Proof of Concept (PTQ-11-04872)**

Funding: Torres Quevedo Award

Duration: 13/04/2012- 12/04/2015

PI: Joan Perello Role: co-Investigator

Project Title: **SNF472 - Phase I Clinical Trials, Efficacy and ADME Studies (RTC-2014-2460-1)**

Funding: RETOS

Duration: 01/02/2014 - 31/03/2016

PI: Francesc Maduell Role: co-Investigator

Project Title: **SNF472. Regulatory non-clinical and clinical studies.**

Funding: CDTI (Centre for the Technological and Industrial Development), Spanish Ministry of Science and Innovation.

Duration: 01/01/2015-31/12/2016

PI: Carolina Salcedo Role: Principal Investigator

Project Title: **Ensayos preclínicos y clínicos regulatorios (ref IDI-20150233)**

Funding: CDTI (Centre for the Technological and Industrial Development), Spanish Ministry of Science and Innovation.

Duration: 01/01/2015 - 31/03/2017

PI: Carolina Salcedo Role: Principal Investigator

Project Title: **Disseny i síntesi de noves molècules derivades de SNF472 amb majors biodisponibilitat i eficàcia potencials (ref ES01/TCAI/76_2016)**

Funding Dirección general de innovación e investigación. Gobierno balear

Duration 09/02/2017- 14/09/2017

PI: Carolina Salcedo Role: Principal Investigator

Project Title: **Recerca de nous sistemes d'administració i alliberació sistèmica alternatius i processos de millora per al procés sintètic del fàrmac SNF472 en desenvolupament pel tractament de la calcificació en malalts de diàlisi (ref ES01/TCAI/77_2016)**

Funding: Dirección general de innovación e investigación. Gobierno balear

Duration 09/02/2017 - 14/09/2017

PI: Carolina Salcedo Role: Principal Investigator

Project Title: **Efecte del SNF472 en la inhibició de la calcificació de vàlvules cardíques (ref ES01/TCAI/41_2017)**

Funding: Dirección general de innovación e investigación. Gobierno balear

Duration 03/10/2017- 14/09/2018

PI: Carolina Salcedo Role: Principal Investigator

Project Title: **Síntesi i caracterització farmacològica de noves molècules derivades mio-inositol (ref ES01/TCAI/40_2017)**

Funding: Dirección general de innovación e investigación. Gobierno balear

Duration : 03/10/2017 - 14/09/2018

PI: Carolina Salcedo Role: Principal Investigator

Project Title: **Síntesi de noves molècules derivades de mio-inositol hexafosfat i avaluació de la biodisponibilitat i eficàcia d'aquestes molècules en estudis in vitro i models in vivo (ref ES01/TCAI/16_2018)**

Funding: Direcció General d'Innovació i Recerca (Gobierno Balear)

Duration 06/08/2018 -31/08/2020

PI: Carolina Salcedo Role: Principal Investigator